Curative Biotechnology (Curative Biotechnology) Debt-to-Equity : -0.08 (As of Mar. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Curative Biotechnology Debt-to-Equity?

Curative Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $1.37 Mil. Curative Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.00 Mil. Curative Biotechnology's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $-17.91 Mil. Curative Biotechnology's debt to equity for the quarter that ended in Mar. 2023 was -0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Curative Biotechnology's Debt-to-Equity or its related term are showing as below:

CUBT's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Curative Biotechnology Debt-to-Equity Historical Data

The historical data trend for Curative Biotechnology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curative Biotechnology Debt-to-Equity Chart

Curative Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

-0.29

-0.12

-0.05

Curative Biotechnology Quarterly Data
	Dec16	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Equity	Get a 7-Day Free Trial															-0.01	-0.03	-0.04	-0.05	-0.08

Competitive Comparison of Curative Biotechnology's Debt-to-Equity

For the Biotechnology subindustry, Curative Biotechnology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curative Biotechnology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curative Biotechnology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Curative Biotechnology's Debt-to-Equity falls into.

Curative Biotechnology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Curative Biotechnology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.071	+	0)	/	-20.53
	=	-0.05

Curative Biotechnology's Debt to Equity Ratio for the quarter that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.369	+	0)	/	-17.912
	=	-0.08

Curative Biotechnology (OTCPK:CUBT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Curative Biotechnology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Curative Biotechnology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Curative Biotechnology (Curative Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curative Biotechnology Inc (OTCPK:CUBT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1825 NW Corporate Boulevard, Suite 110, Boca Raton, FL, USA, 33431

Website

https://www.curativebiotech.com

Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The company currently has ongoing programs in three therapeutic areas: Infectious Disease, Neuro-Oncology, and Degenerative Eye Disease.